Inoviq Valuation Multiples

Discover Inoviq's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Rhythm Biosciences, Abingdon Health, Microba Life Sciences, Nexsen and more.

Inoviq Overview

About Inoviq

Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.


Founded

1983

HQ

Australia

Employees

85

Website

inoviq.com

Financials (LTM)

Revenue: $625K
EBITDA: ($4M)

EV

$19M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Inoviq Financials

Inoviq reported last 12-month revenue of $625K and negative EBITDA of ($4M).

In the same LTM period, Inoviq generated $416K in gross profit, ($4M) in EBITDA losses, and had net loss of ($6M).


Inoviq P&L

In the most recent fiscal year, Inoviq reported revenue of $379K and EBITDA of ($4M).

Inoviq is unprofitable as of last fiscal year, with gross margin of 78%, EBITDA margin of (926%), and net margin of (1189%).

See analyst estimates for Inoviq
LTMLast FY202320242025202620272028
Revenue$625K$379K$323K$374K$500K
Gross Profit$416K$295K$279K$305K$355K
Gross Margin67%78%87%81%71%
EBITDA($4M)($4M)($6M)($5M)($5M)
EBITDA Margin(663%)(926%)(1710%)(1279%)(913%)
EBIT Margin(961%)(1252%)(1962%)(1508%)(1188%)
Net Profit($6M)($5M)($5M)($5M)($5M)
Net Margin(928%)(1189%)(1663%)(1246%)(1059%)

Financial data powered by Morningstar, Inc.

Inoviq Stock Performance

Inoviq has current market cap of $28M, and enterprise value of $19M.


Inoviq's stock price is $0.20.

Inoviq share price decreased by 46.6% in the last 30 days.

Inoviq has an EPS (earnings per share) of $-0.03.

See more trading valuation data for Inoviq
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$19M$28M0.4%-46.6%--$-0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Inoviq Valuation Multiples

Inoviq trades at 30.2x EV/Revenue multiple, and (4.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Inoviq

Inoviq Financial Valuation Multiples

As of July 2, 2026, Inoviq has market cap of $28M and EV of $19M.

Inoviq has a P/E ratio of (4.9x).

LTMLast FY202320242025202620272028
EV/Revenue30.2x49.8x58.5x50.4x37.7x
EV/EBITDA(4.5x)(5.4x)(3.4x)(3.9x)(4.1x)
EV/EBIT(3.1x)(4.0x)(3.0x)(3.3x)(3.2x)
EV/Gross Profit45.3x63.9x67.6x61.9x53.2x
P/E(4.9x)(6.3x)(5.3x)(6.1x)(5.3x)
EV/FCF(3.8x)(6.1x)(4.6x)(5.9x)(4.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Inoviq Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Inoviq Margins & Growth Rates

Inoviq grew revenue by 64% and EBITDA by 18% in the last fiscal year.

In the most recent fiscal year, Inoviq reported gross margin of 78%, EBITDA margin of (926%), and net margin of (1189%).

See estimated margins and future growth rates for Inoviq

Inoviq Margins

Last FY202420252026202720282029
Gross Margin78%81%71%64%
EBITDA Margin(926%)(1279%)(913%)(479%)
EBIT Margin(1252%)(1508%)(1188%)(650%)
Net Margin(1189%)(1246%)(1059%)(625%)
FCF Margin(823%)(856%)(827%)(543%)

Inoviq Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth64%16%34%93%
Gross Profit Growth40%9%16%75%
EBITDA Growth18%(13%)(5%)1%
EBIT Growth27%(11%)5%6%
Net Profit Growth29%(13%)14%14%
FCF Growth59%(22%)29%27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Inoviq Operational KPIs

Inoviq's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.

Inoviq's Rule of 40 is (385%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Inoviq's Rule of X is (245%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Inoviq
LTMLast FY202320242025202620272028
Rule of 40(551%)(385%)---
Bessemer Rule of X(383%)(245%)---
Revenue per Employee-$0.0M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-86%129%84%65%
G&A Expenses to Revenue-869%708%736%658%
R&D Expenses to Revenue-309%635%406%234%
Opex to Revenue-1629%2049%1590%1234%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Inoviq Competitors

Inoviq competitors include Rhythm Biosciences, Abingdon Health, Microba Life Sciences, Nexsen, Urteste, Genematrix, BCAL Diagnostics, Read-Gene, Cryosite and Glycorex Transplantation.

Most Inoviq public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Rhythm Biosciences1350.0x-(9.5x)-
Abingdon Health2.7x1.9x(8.9x)(23.1x)
Microba Life Sciences1.4x1.3x(2.0x)(1.8x)
Nexsen----
Urteste3180.1x-(12.9x)-
Genematrix1.6x-(14.7x)-
BCAL Diagnostics9.8x-(4.2x)-
Read-Gene3.9x-68.0x-

This data is available for Pro users. Sign up to see all Inoviq competitors and their valuation data.

Start Free Trial

Acquisitions by Inoviq

Inoviq has acquired 1 company to date.

Last acquisition by Inoviq was on July 1st 2020. Inoviq acquired Sienna Cancer Diagnostics for $16M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Inoviq

Sienna Cancer Diagnostics
Description
Sienna Cancer Diagnostics is a Perth-based developer of in vitro diagnostic tests and reagents for cancer detection. The company commercializes biomarkers for prostate, bladder, and breast cancers through partnerships with global labs and hospitals. Sienna's portfolio includes Progensa PCA3 assay for prostate cancer risk assessment and collaborates with clinical networks in Australia, Europe, and Asia for validation and distribution.
HQ CountryAustralia
HQ City
Melbourne
Deal Date1 Jul 2020
Valuation$16M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Inoviq acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Inoviq

When was Inoviq founded?Inoviq was founded in 1983.
Where is Inoviq headquartered?Inoviq is headquartered in Australia.
How many employees does Inoviq have?As of today, Inoviq has over 85 employees.
Is Inoviq publicly listed?Yes, Inoviq is a public company listed on Australian Securities Exchange.
What is the stock symbol of Inoviq?Inoviq trades under IIQ ticker.
When did Inoviq go public?Inoviq went public in 1991.
Who are competitors of Inoviq?Inoviq main competitors include Rhythm Biosciences, Abingdon Health, Microba Life Sciences, Nexsen, Urteste, Genematrix, BCAL Diagnostics, Read-Gene, Cryosite, Glycorex Transplantation.
What is the current market cap of Inoviq?Inoviq's current market cap is $28M.
What is the current revenue of Inoviq?Inoviq's last 12 months revenue is $625K.
What is the current revenue growth of Inoviq?Inoviq revenue growth (NTM/LTM) is 112%.
What is the current EV/Revenue multiple of Inoviq?Current revenue multiple of Inoviq is 30.2x.
Is Inoviq profitable?No, Inoviq is not profitable.
What is the current EBITDA of Inoviq?Inoviq has negative EBITDA and is not profitable.
What is Inoviq's EBITDA margin?Inoviq's last 12 months EBITDA margin is (663%).
What is the current EV/EBITDA multiple of Inoviq?Current EBITDA multiple of Inoviq is (4.5x).
What is the current FCF of Inoviq?Inoviq's last 12 months FCF is ($5M).
What is Inoviq's FCF margin?Inoviq's last 12 months FCF margin is (796%).
What is the current EV/FCF multiple of Inoviq?Current FCF multiple of Inoviq is (3.8x).
How many companies Inoviq has acquired to date?As of July 2026, Inoviq has acquired 1 company.
What was the largest acquisition by Inoviq?$16M acquisition of Sienna Cancer Diagnostics on 1st July 2020 was the largest M&A Inoviq has done to date.
What companies Inoviq acquired?Inoviq acquired Sienna Cancer Diagnostics.
In how many companies Inoviq has invested to date?Inoviq hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Inoviq

Lists including Inoviq

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial